Analysts Set Liquidia Co. (NASDAQ:LQDA) PT at $25.38

Liquidia Co. (NASDAQ:LQDA) has been assigned an average recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $25.38.

A number of analysts recently commented on the stock. Scotiabank initiated coverage on shares of Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital started coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price for the company. Wells Fargo & Company initiated coverage on shares of Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of Liquidia in a report on Thursday, January 9th.

Insider Activity at Liquidia

In related news, insider Rajeev Saggar sold 6,249 shares of the firm’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $73,613.22. Following the transaction, the insider now directly owns 270,388 shares of the company’s stock, valued at approximately $3,185,170.64. This trade represents a 2.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the transaction, the chief executive officer now owns 1,019,177 shares in the company, valued at $12,005,905.06. This trade represents a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,055 shares of company stock worth $836,299 over the last quarter. Company insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Quest Partners LLC purchased a new stake in shares of Liquidia during the second quarter worth about $27,000. Clear Harbor Asset Management LLC bought a new position in shares of Liquidia during the third quarter worth $100,000. Signaturefd LLC grew its stake in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after acquiring an additional 9,984 shares in the last quarter. Ballentine Partners LLC bought a new stake in Liquidia in the 3rd quarter valued at $110,000. Finally, Whitcomb & Hess Inc. lifted its stake in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after purchasing an additional 1,074 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Price Performance

Shares of LQDA opened at $12.89 on Friday. The firm has a market cap of $1.09 billion, a PE ratio of -7.91 and a beta of 0.23. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.99. The stock’s fifty day moving average price is $11.30 and its two-hundred day moving average price is $11.04.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).